Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Quince Therapeutics, Inc. (QNCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/18/2025: QNCX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 149.51% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.84M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 121683 | Beta 0.71 | 52 Weeks Range 0.51 - 2.45 | Updated Date 03/30/2025 |
52 Weeks Range 0.51 - 2.45 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual -0.2839 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.5% | Return on Equity (TTM) -79.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30789119 | Price to Sales(TTM) - |
Enterprise Value 30789119 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.44 | Shares Outstanding 43276600 | Shares Floating 34603109 |
Shares Outstanding 43276600 | Shares Floating 34603109 | ||
Percent Insiders 13.74 | Percent Institutions 25.24 |
Analyst Ratings
Rating 4.67 | Target Price 12 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quince Therapeutics, Inc.
Company Overview
History and Background
Quince Therapeutics, Inc., formerly Cortexyme, Inc., is a biopharmaceutical company focusing on novel therapies for debilitating diseases. Founded in 2012, it initially concentrated on Alzheimer's disease before expanding its pipeline through strategic acquisitions and internal development.
Core Business Areas
- Bone-targeting programs: Developing therapies designed to target and treat bone diseases.
- Discovery platform: Leveraging its scientific expertise to identify and develop new drug candidates.
Leadership and Structure
The leadership team includes Dirk Thye (CEO), along with a board of directors providing strategic oversight. The organizational structure is functional, with departments for research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- BMS-986263: Quince acquired this asset in 2024, a late-stage asset with blockbuster potential in late-stage trials for pulmonary diseases. Competitive landscape: Boehringer Ingelheim, Roche, Gilead.
- QUINC-208: A bone-targeting drug delivery platform, currently in early clinical development. Competitors: Selecta Biosciences, Compass Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. It is driven by innovation and the development of novel therapies to address unmet medical needs.
Positioning
Quince Therapeutics, Inc. is positioning itself as a specialized pharmaceutical company with a focus on innovative therapies and diseases with high unmet needs.
Total Addressable Market (TAM)
The TAM for targeted therapies varies greatly depending on the indication but can reach billions of dollars for prevalent diseases. Quince is aiming for niche segments within this larger market.
Upturn SWOT Analysis
Strengths
- Novel drug delivery platform
- Experienced management team
- Focus on unmet medical needs
- Strategic partnerships and acquisitions
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
- Early stage development focus increases risk
Opportunities
- Expansion into new therapeutic areas
- Strategic collaborations and licensing deals
- Positive clinical trial results
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent expiration
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- AMGN
Competitive Landscape
Quince Therapeutics, Inc. faces stiff competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel technologies.
Major Acquisitions
BMS-986263
- Year: 2024
- Acquisition Price (USD millions): 10
- Strategic Rationale: Acquired to broaden product pipeline and target pulmonary diseases
Growth Trajectory and Initiatives
Historical Growth: Quince Therapeutics, Inc.'s growth has been primarily driven by acquisitions and internal development. Revenue is limited.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analysts expect significant revenue growth if key pipeline products are approved.
Recent Initiatives: Recent initiatives include acquiring pipeline assets and advancing clinical programs.
Summary
Quince Therapeutics, Inc. is a high-risk, high-reward biopharmaceutical company with a focus on novel therapies. It faces significant competition and requires successful clinical trial outcomes to achieve long-term growth. However, its innovative platform and strategic acquisitions position it for potential success in addressing unmet medical needs. Significant cash burn and dependence on trial success are major risks.
Similar Companies
- CRIS
- SAVA
- ALNY
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quince Therapeutics, Inc.
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-09 | CEO, Chief Medical Officer & Director Dr. Dirk Thye M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.quincetx.com |
Full time employees 36 | Website https://www.quincetx.com | ||
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.